3 Under-the-Radar Biotech Stocks to Buy in 2023
Most people have either had cancer themselves or know someone who has. According to the American Cancer Society, 1 in 3 people in the U.S. will be diagnosed with one of the numerous forms of cancer.
Deciphera Pharmaceuticals (NASDAQ: DCPH), Mirati Therapeutics (NASDAQ: MRTX) and MacroGenics (NASDAQ: MGNX) are lesser-known biotech companies with significant potential since they focus on oncology therapies. However, the stock prices of all three have fallen this year, meaning their shares can still be bought at a decent price point.
All three have seen a boost in second-quarter finances and have late-stage therapies with promise in their pipelines.
Source Fool.com
Mirati Therapeutics Inc. Aktie
53,84 €
-0,04 %
Die Community zeigt eine Präferenz für Sell-Einschätzungen bei Mirati Therapeutics Inc..
Obwohl das Kursziel für Mirati Therapeutics Inc. bei 78 € liegt, was über dem aktuellen Kurs von 53.84 € ist, zeigt sich ein Potenzial von 44.87%.
